RLFFD Stock Price, News & Analysis
RLFFD
Company Description
RELIEF THERAPEUTICS Holding SA (RLFFD) is a biopharmaceutical company focused on delivering innovative treatment options for select specialty and rare diseases. With a commitment to advancing treatment paradigms, the company's portfolio includes marketed products, proprietary platform technologies, and a clinical development pipeline targeting rare metabolic, dermatology, and respiratory diseases. Relief Therapeutics' mission is to provide therapeutic relief to those suffering from rare diseases, supported by an experienced team of biopharma industry leaders.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$47.4M
Market Cap
0.0
Shares outstanding
Latest News
SEC Filings
No SEC filings available for RLFFD.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the market cap of RLFFD (RLFFD)?
The market cap of RLFFD (RLFFD) is approximately 47.4M.
What is RELIEF THERAPEUTICS Holding SA focused on?
RELIEF THERAPEUTICS Holding SA is focused on delivering innovative treatment options for select specialty and rare diseases.
What does the company's portfolio consist of?
The company's portfolio includes marketed products, proprietary platform technologies, and a clinical development pipeline targeting rare metabolic, dermatology, and respiratory diseases.
What is RELIEF THERAPEUTICS' mission?
RELIEF THERAPEUTICS' mission is to provide therapeutic relief to those suffering from rare diseases.
Where is RELIEF THERAPEUTICS headquartered?
RELIEF THERAPEUTICS is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany, and Monza, Italy.
What is the stock symbol for RELIEF THERAPEUTICS?
The stock symbol for RELIEF THERAPEUTICS is RLFFD.
Where can I find more information about RELIEF THERAPEUTICS?
You can visit RELIEF THERAPEUTICS' website at www.relieftherapeutics.com or follow them on LinkedIn and Twitter.